Peptide antagonists of vascular endothelial growth factor

Details Peptide antagonists of vascular endothelial growth factor Peptide antagonists of vascular endothelial growth factor

2004-06-02

2008-08-19

Saoud, Christine J (Department: 1647)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Peptide containing doai

C514S002600, C530S399000, C530S300000, C530S324000

Reexamination Certificate

active

07414027

ABSTRACT:
The present invention provides isolated polypeptides having VEGF antagonist activity, pharmaceutical compositions and methods of treatment. The polypeptides of the invention include polypeptides comprising a portion of SEQ ID NO: 1 having VEGF antagonist activity, polypeptides comprising SEQ ID NO: 2 or a portion thereof having VEGF antagonist activity, and a polypeptide having the structure of formula (I), set forth above. The present invention further includes analogs and derivatives of these polypeptides having VEGF antagonist activity.

REFERENCES:
patent: 5219739 (1993-06-01), Tischer et al.
patent: 6777534 (2004-08-01), Klagsbrun et al.
patent: 0 599 274 (1994-06-01), None
patent: WO 96/06641 (1996-03-01), None
patent: WO 97/08313 (1997-03-01), None
S. Soker et al., “Characterization of Novel Vascular Endothelial Growth factor (VGEF) Receptors on Tumor Cells that Bind VEGF165via its Exon 7-Encoded Domain,”J. Biol. Chem., 271(10):5761-5767, 1996.
S. Soker et al., “Inhibition of Vascular Endothelial Growth factor (VEGF)-Induced Endothelial Cell Proliferation by a Peptide Corresponding to the Exon 7-Encoded Domain of VEGF165,”J. Biol. Chem., 272(50):31582-31588, 1997.
S. Soker et al., “Neuropilin-1 is Expressed by Endothelial and Tumor Cells as an Isoform-Specific Receptor for Vascular Endothelial Growth Factor,”Cell, 92:735-745, 1998.
S. Gengrinovitch et al., “Platelet Factor-4 Inhibits the Mitogenic Activity of VEGF121and VEGF165Using Several Concurrent Mechanisms,”J. Biol. Chem., 270(25):15059-15065, 1995.
T. Omura et al., “Identification of a 190 kDa Vascular Endothelial Growth factor 165 Cell Surface Binding Protein on a Human Glioma Cell Line,”J. Biol. Chem., 272(37):23317-23322, 1997.
Burgess et al., “Possible Dissociation of the Heparin-binding and Mitogenic Activities of Heparin-binding (Acidic Fibroblast) Growth Factor-1 from Its Receptor-binding Activities by Site-directed Mutagenesis of a Single Lysine Residue”,J of Cell Bio. 111:2129-2138, 1990.
Lazar et al., “Transforming Growth Factor alpha: Mutation of Aspartic Acid 47 and Leucine 48 Results in Different Biological Activities”,Molecular and Cellular Biology8:1247-1252, 1988.
Bowie et al., “Deciphering the Message in Protein Sequences: Tolerance to Amino Acid Substitutions”,Science, 247:1306-1310, 1990, p. 1306, col. 2.
Fleurbaaij et al. (WO/9606641), Mar. 1996, Accession No. AAR94041, Sequence comparison.
Plowman et al., “Ligand-Specific Activation of HER4/p180erbB4 a Fourth Member of the Epidermal Growth Factor Receptor Family”,Proc. Natl. Acad. Sci., vol. 90, Mar. 1993, pp. 1746-1750.
Siegall et al., “Activity of HER4 Targeted Ligand-Toxin Fusion Proteins Against Human Tumors”,Proc. Am. Assoc. Cancer Res. Ann. Meet., vol. 35, No. 2276, Mar. 1994, p. 382.
Tzahar et al., “ErbB-3 and ErbB-4 Function as the Respective Low and High Affinity Receptors of All Neu Differentiation Factor/Heregulin Isoforms”,J. Biol. Chem., vol. 269, No. 40, Oct. 7, 1994, pp. 25226-25233.
Nagata et al., “Solution Structure of the Epidermal Growth Factor-like Domain of Heregulin-alpha, a Ligand for p180erbB-4”, Embo J., vol. 13, No. 15, Aug. 1, 1994, pp. 3517-3523.
Culouscou et al., “Characterization of a Breast Cancer Cell Differentiation Factor That Specifically Activates the HER4/p180erbB4Receptor”,J. Biol. Chem., vol. 268, No. 25, Sep. 5, 1993, pp. 18407-18410.
Siegal, et al., “HER4 Expression Correlates with Cytotoxicity Directed by a Heregulin-Toxin Fusion Protein”,J. Biol. Chem., vol. 270, No. 13, Mar. 31, 1995, pp. 7623-7630.
Kihara et al., “Cytotoxic Activity of Chimeric Toxins Containing the Epidermal Growth Factor-like Domain of Heregulins Fused to PE38KDEL, a Truncated Recombinant Form of Pseudomonas Exotoxin”,Cancer Res., vol. 55, Jan. 1, 1995, pp. 71-77.
Jeschke et al., “Targeted Inhibition of Tumor-cell Growth by Recombinant Heregulin-toxin Fusion Proteins”,Int. J. Cancer, vol. 60, No. 5, Mar. 3, 1995, pp. 730-739.

Affiliated with

Also associated with

Rating

Peptide antagonists of vascular endothelial growth factor does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Peptide antagonists of vascular endothelial growth factor, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Peptide antagonists of vascular endothelial growth factor will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4005493